Meha Ballard, RN, MSN

Intercept Pharmaceuticals, Inc.

Poster(s):

• P1744 - Combined Effect of Obeticholic Acid and Bezafibrate in Patients With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid: 6-Month Results From a Phase 2 Trial
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET